Acadia Pharmaceuticals reported $112.52M in Gross Profit on Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US $ 112.52M 15.68M
ALKERMES ALKS:US 223.39M 47.4M
Alnylam Pharmaceuticals ALNY:US $ 177.63M 43.24M
Biogen BIIB:US $ 1777.9M 295.8M
Biomarin Pharmaceutical BMRN:US $ 402.39M 72.33M
Bristol Myers Squibb BMY:US $ 9177M 452M
Corcept Therapeutics CORT:US $ 97.47M 2.61M
Eisai 4523:JP Y 158750M 35913M
Eli Lilly And LLY:US $ 5737.9M 211.8M
Intercept Pharmaceuticals ICPT:US $ 87.82M 3.57M
Intra Cellular Therapies ITCI:US $ 31.84M 8.71M
Johnson & Johnson JNJ:US $ 15828M 1021M
Marinus Pharmaceuticals MRNS:US 13.02M 11.5M
Moderna Inc MRNA:US 5.05B 1.21B
Neurocrine Biosciences NBIX:US $ 306M 1.9M
Pfizer PFE:US $ 15651M 1516M
Sarepta Therapeutics SRPT:US $ 179.39M 9.67M
Seattle Genetics SGEN:US $ 338.83M 4.33M
Ultragenyx Pharmaceutical RARE:US $ 73.83M 6.04M
Vertex Pharmaceuticals VRTX:US $ 1851.7M 26.53M
YTE INCY:US $ 696.02M 128.26M